top of page


NICE backs Padcev and Keytruda combination around surgery for muscle-invasive bladder cancer
NICE has issued positive final draft guidance for perioperative Padcev and Keytruda in muscle-invasive bladder cancer, potentially expanding NHS treatment access before and after surgery for eligible patients regardless of cisplatin suitability.

nuaxia
5 days ago2 min read


European Commission launches eligibility checker for EU Joint Clinical Assessments
The new tool is intended to help health technology developers determine whether a medicinal product falls within the EU’s Joint Clinical Assessment requirements before entering the formal HTA process.

nuaxia
Aug 123 min read


EU Joint Clinical Assessment enters second year as pharmaceutical companies adapt evidence strategies
The EU Health Technology Assessment Regulation now requires eligible oncology medicines and advanced therapies to undergo a single European clinical assessment, increasing the importance of early evidence planning alongside EMA regulatory development.

nuaxia
Aug 113 min read
bottom of page